H.C. Wainwright raised the firm’s price target on Entrada Therapeutics (TRDA) to $20 from $18 and keeps a Buy rating on the shares following the Q3 report. The company has two candidates approaching mid-stage clinical trial entry, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA: